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Background: Low 25-hydroxy vitamin D (25(OH)D) levels have been associated with an increased risk of
albuminuria, however an association with glomerular filtration rate (GFR) is not clear. We explored the relationship
between 25(OH)D levels and prevalent chronic kidney disease (CKD), albuminuria and impaired GFR, in a national,
population-based cohort of Australian adults (AusDiab Study).
Methods: 10,732 adults ≥25 years of age participating in the baseline survey of the AusDiab study (1999–2000)
were included. The GFR was estimated using an enzymatic creatinine assay and the CKD-EPI equation, with CKD
defined as eGFR <60 ml/min/1.73 m2. Albuminuria was defined as a spot urine albumin to creatinine ratio (ACR) of
≥2.5 mg/mmol for men and ≥3.5 for women. Serum 25(OH)D levels of <50 nmol/L were considered vitamin D
deficient. The associations between 25(OH)D level, albuminuria and impaired eGFR were estimated using
multivariate regression models.
Results: 30.7% of the study population had a 25(OH)D level <50 nmol/L (95% CI 25.6-35.8). 25(OH)D deficiency was
significantly associated with an impaired eGFR in the univariate model (OR 1.52, 95% CI 1.07-2.17), but not in the
multivariate model (OR 0.95, 95% CI 0.67-1.35). 25(OH)D deficiency was significantly associated with albuminuria in
the univariate (OR 2.05, 95% CI 1.58-2.67) and multivariate models (OR 1.54, 95% CI 1.14-2.07).
Conclusions: Vitamin D deficiency is common in this population, and 25(OH)D levels of <50 nmol/L were
independently associated with albuminuria, but not with impaired eGFR. These associations warrant further
exploration in prospective and interventional studies.
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Vitamin D plays an important role in human health, and
vitamin D deficiency is commonly observed in the general
population and across the spectrum of chronic kidney dis-
ease (CKD) [1]. Traditionally, vitamin D has been linked to
bone and mineral metabolism, however increasingly it has
been also recognised to play a pivotal role in the physi-
ology of numerous other organs including the endocrine,
cardiovascular and immune systems [2].* Correspondence: matthew.damasiewicz@monash.edu
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distribution, and reproduction in any mediumCKD affects between 10-15% of the adult population
[3]. The decline in renal function is paralleled by a re-
duction in calcitriol synthesis, and calcitriol replacement
has been associated with improved mortality in patients
with CKD [4–7]. Many extra-renal cells are able to con-
vert the circulating form of vitamin D, 25-hydroxy vita-
min D (25(OH)D), into the active form [8]. This has
focused research on the autocrine function of vitamin D,
and serum 25(OH)D deficiency has emerged as an im-
portant independent risk factor for morbidity and mor-
tality, and a potential therapeutic target in CKD.
Experimental data show that vitamin D is a potent in-
hibitor of the renin-angiotensin system (RAS) [9] and
nuclear factor (NF)-kB pathway [10], and in humanentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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associated with higher plasma renin and angiotensin 2
concentrations [11]. These pathways play an important
role in the pathogenic processes of kidney disease, medi-
ating immune, inflammatory and proliferative effects that
culminate in progressive renal damage [12]. 25(OH)D
deficiency may potentiate the decline in renal function as
well as the progression of albuminuria, which is in itself
an established predictor of CKD progression and cardio-
vascular outcomes [13–15].
In general population studies such as the Third
National Health and Nutrition Examination Survey
(NHANES III), 25(OH)D deficiency has been associated
with prevalent albuminuria [16] and progression to end-
stage kidney disease (ESKD) [17]. In a population aged
65 years and older, 25(OH)D deficiency was associated
with glomerular filtration rate (GFR) loss [18]. In the
CKD population 25(OH)D deficiency has also been asso-
ciated with prevalent albuminuria [19], progression to
ESKD [20] and mortality [21]. In a recent meta-analysis
higher 25(OH)D levels were associated with improved
survival [22].
In a large, general population cohort of adults aged
25 years and over participating in the AusDiab study, we
examine the cross-sectional association of 25(OH)D
levels with albuminuria and impaired GFR. Existing lit-
erature supports an association between 25(OH)D and
albuminuria, however its association with renal function
is less clear. We hypothesized that 25(OH)D deficiency
would be highly prevalent and associated with CKD,
however this association is likely to be stronger with
albuminuria rather than decreased eGFR.
Methods
Study population
AusDiab was a population-based survey of adults aged
25 years and older, which used cross-sectional data col-
lected at baseline (1999–2000). Details of the survey
methods and sample collection have been previously
described in detail [23]. In brief, a sample of the popula-
tion was obtained using a stratified sampling cluster
method. Of 17,129 households eligible for inclusion,
11,479 agreed to be interviewed and 20,293 adults com-
pleted the household interview. A total of 11,247 (55.3%)
adults presented for the physical examination. A
complete data set was available for 10,732 (95.4%), and
was used in all analyses. The overall response rate for
the study was approximately 37%. The AusDiab study
was approved by the International Diabetes Institute
ethics committee (Melbourne, Australia), and written
informed consent was obtained from all participants.
The consent included permission for any data obtained
at the time of the baseline analysis to be used in future
studies.Study measurements
Details of the biomedical tests have been previously
reported [23,24]. In brief, those who attended a testing
site at baseline underwent a physical examination, which
consisted of a fasting blood sample, a random spot urine
morning collection and a standard 75-g oral glucose
tolerance test. Demographic data and information were
collected using standardized interviewer-administered
questionnaires.
Hypertension was defined as a systolic blood pressure of
140 mmHg or greater or a diastolic blood pressure of
90 mmHg or greater. Body mass index (BMI) was calcu-
lated from weight and height measurements, with the
diagnosis of obesity defined as a body mass index of
30 kg/m2 or greater. Standard World Health Organization
criteria for the diagnosis of abnormal glucose metabolism
were used. Diabetes was diagnosed on the basis of fasting
plasma glucose level of 7.0 mmol/L (126.1 mg/dl) or
greater, 2-hour plasma glucose level of 11.1 mmol/L
(200 mg/dl) or greater, or current treatment with insulin
or oral hypoglycemic medication. Smoking status was self-
reported, and subjects were classified as either current
smoking or non-smoking (ex-smokers and never smoked).
Cholesterol and triglyceride levels were measured on fast-
ing serum samples, and assessed as continuous variables.
Cardiovascular disease was assessed using self-reported
symptoms or past history. Ethnicity was categorized into
“Europid” and “non-Europid” based on the country of
birth. The majority of participants were classified as “Euro-
pid”, which included those born in Australia, New
Zealand, North America and Northern Europe. Time of
assessment was classified by the season in which
venipuncture was performed. The location of the subjects
(urban versus rural) was based upon the classification used
by the Australian Bureau of Statistics. The latitude of
blood collection centers was determined using the Goo-
gleW GPS tool and entered as a continuous variable for
analysis (range 12°S to 43°S). Total leisure-time physical
activity reported for the previous week (none, insufficient:
1–149 min; sufficient: ≥150 min) was measured using the
Active Australia questionnaire, which is the standard
instrument for population surveillance and has acceptable
reliability [25].
Laboratory methods
Serum 25(OH)D was measured in the entire baseline
AusDiab cohort from samples, which were stored at −80°C.
A direct competitive chemiluminescent immunoassay
(CLIA) was performed in our laboratory using a Liaison
analyser (DiaSorin Inc., Stillwater, MN, USA) with an inter-
assay CV of 7.0% at 45 nmol/L and 6.3% at 93 nmol/L.
For participants where fasting serum was not available
(n=210), fluoride oxalate plasma was used. To evaluate
whether fluoride oxalate plasma was comparable with
Table 1 Characteristic of the cohort by vitamin D
deficiency








Age (mean, [SE]) 48.2 [0.82] 46.8 [0.92] 51.3 [0.68] <0.001
Age group
25–44 (%, [SE]) 47.5 [2.48] 51.3 [2.80] 39.0 [1.94]
45–64 (%, [SE]) 33.9 [1.85] 32.1 [2.11] 37.8 [1.61]
≥65 (%, [SE]) 18.6 [1.80] 16.6 [1.93] 23.2 [1.85] <0.001
Female (% [SE]) 49.9 [0.57] 44.0 [0.70] 63.8 [1.71] <0.001
Europid (% [SE]) 87.3 [2.74] 92.1 [1.76] 76.6 [4.48] <0.001
Diabetes (% [SE]) 7.0 [0.66] 5.1 [0.49] 11.1 [1.04] <0.001
Hypertension (% [SE]) 22.5 [1.45] 20.0 [1.74] 28.0 [0.97] <0.001
Smoking (% [SE]) 16.4 [1.77] 16.4 [1.72] 16.4 [2.72] 0.98
Current
History of CVD (% [SE]) 6.1 [0.57] 5.1 [0.52] 8.2 [0.80] <0.001
Season (% [SE])
summer (Dec –Feb) 12.8 [6.72] 16.3 [8.27] 4.9 [2.72] <0.001
autumn (Mar –May) 14.2 [5.10] 13.3 [4.81] 16.2 [6.04]
winter (Jun –Aug) 26.7 [5.56] 23.3 [5.22] 34.3 [7.31]
spring (Sep –Nov) 46.3 [7.07] 47.1 [7.86] 44.7 [6.56]
BMI (% [SE])
25–29.9 39.2 [0.56] 40.7 [0.78] 36.1 [1.28] <0.001
≥ 30 20.3 [1.05] 17.3 [1.17] 27.0 [1.60]
Total cholesterol (mean [SE]) 5.54 [0.03] 5.43 [0.03] 5.79 [0.03] <0.001
Location (%, [SE]) Urban 57.0 [10.5] 53.8 [10.7] 64.1 [11.0] 0.11
Albuminuria (%, [SE]) 6.9 [0.60] 5.4 [0.52] 10.5 [1.05] <0.001
eGFR< 60 (%, [SE]) 2.7 [0.28] 2.3 [0.30] 3.5 [0.47] 0.03
SE – standard error, CVD - cardiovascular disease, BMI – body mass index,
eGFR – estimated glomerular filtration rate.
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lysed both simultaneously from samples collected from 101
laboratory staff. There was excellent agreement between the
two tubes: fluoride oxalate plasma 25(OH)D=0.97 x serum
25(OH)D+2.5, r² = 0.89 [26].
Serum creatinine was reassessed on all baseline sam-
ples using an IDMS aligned enzymatic method (Roche
Modular, Roche Diagnostics, Indianapolis IN). Urine al-
bumin was measured by means of rate nephelometry
with the Beckman Array (Beckman/Coulter, Fullerton,
USA) using fresh urine samples at the time of original
collection. Urine creatinine was measured using the
modified kinetic Jaffé reaction using an Olympus AU600
autoanalyzer (Olympus Optical Co. Ltd., Tokyo, Japan).
Study outcomes
Vitamin D deficiency was defined as a serum 25(OH)D
level of <50 nmol/L [27,28]. For subgroup analysis, com-
mon clinical cut-points were used, with 25(OH)D levels
of <75, <50 and <25, classified as insufficient, deficient
and severely deficient. Microalbuminuria was defined as
a urine albumin-creatinine ratio (ACR) of ≥2.5 mg/mmol
in males and ≥3.5 in females, with macroalbuminuria
defined as a urine ACR of ≥25 mg/mmol [29]. GFR was
estimated using the Chronic Kidney Disease epidemi-
ology (CKD-EPI) equation for white men and women
[30]. Impaired GFR was defined as an eGFR <60 ml/
min/1.73 m2 [31].
Statistical analysis
Analyses were weighted to represent the non-
institutionalized Australian population, accounting for
non-response and the stratified cluster sampling method
of the survey design to produce nationally representative
estimates. All estimated means, proportions, odds ratios,
and their standard errors, were adjusted for the survey
design by using the survey commands for analyzing com-
plex survey data. Urine ACR was natural log transformed
because of the skewed nature of the data.
Logistic regression was used to assess the relationship
between the two separate CKD variables (albuminuria
and impaired eGFR) and the odds of vitamin D defi-
ciency. Three models were performed: unadjusted,
adjusted for gender and age, and fully adjusted. Covari-
ates examined included age, gender, BMI, cholesterol,
triglycerides, cardiovascular disease, smoking status, eth-
nicity, diabetic status, location (urban or rural), latitude,
season, exercise, ethnicity and blood pressure. The albu-
minuria models were also adjusted for eGFR, and the
eGFR models were adjusted for albuminuria. The fully
adjusted multivariate model was constructed including
covariates if they were clinically important or confoun-
ders. Finally we used multinomial logistic regression to
explore the relationship between levels and severity ofalbuminuria and eGFR and vitamin D deficiency. Inter-
actions between the CKD outcomes and age, sex, dia-
betes mellitus were also assessed. All analyses were
conducted using Stata/IC, version 11.1 (Stata Corp,
College Station, TX).Results
Table 1 summarises the baseline characteristics of the
total population, and stratified by 25(OH)D deficiency.
10,732 participants in the baseline survey were included
in the final analysis. The mean age of the subjects was
48.2 years (95% CI 46.5-49.9).
The mean 25(OH)D level was 62.8 nmol/L (95% CI
58.8-66.8). The proportion of study participants with a
25(OH)D level of <25, 25–49, 50–74 and ≥75 nmol/L
was 4.1%, 26.6%, 42.1% and 27.2%, respectively. Mean 25
(OH)D levels were lower in females (57.9 versus
67.7 nmol/L, p< 0.001) and non-Europids (47.1 versus
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those aged 25–44, 45–64 and >65 years were 67.1 (95%
CI, 61.6-72.6), 59.8 (95% CI 56.9-62.6) and 57.3 (95% CI
54.1-60.4) nmol/L (p trend <0.001), respectively. 25(OH)
D deficiency was more prevalent with increasing age, fe-
male gender, non-European background, medical co-
morbidities (diabetes, hypertension, cardiovascular dis-
ease, obesity) and the presence of albuminuria and an
impaired GFR (Table 1).
Impaired eGFR
The mean eGFR in the study cohort was 99.1 ml/min/
1.73 m2 (95% CI, 97.7-100.6). The proportion of study
participants with an eGFR of <60 ml/min/1.73 m2, was
2.7% (95% CI 2.1-3.3). Of these participants, the propor-
tion with CKD stage 3a, 3b, and 4/5 was 70.5%, 19.4%,
and 10.2%, respectively. The mean 25(OH)D levels were
lower in those with an eGFR of <60, (57.2 versus
63.0 nmol/L, p= 0.02). 25(OH)D deficiency was signifi-
cantly associated with an eGFR <60 ml/min/1.73 m2 in
the unadjusted model (OR 1.52, 95% CI 1.07-2.17,
p= 0.02). However the association was attenuated and no
longer significant when adjusted for age and gender (OR
0.96, 95% CI, 0.71-1.30), p= 0.78), and in the fully
adjusted model (OR 0.95, 95% CI, 0.67-1.35, p= 0.78).
The relationship between vitamin D level and eGFR
was further explored with the study population being
divided into quartiles based upon the 25(OH)D and
population cut-off levels (Table 2). 25(OH)D levels in theTable 2 Impaired eGFR regression models - vitamin D
quartiles study population & population cut-off points
eGFR <60 OR (95% CI)
25(OH)D level nmol/L Model 1a Model 2b Model 3c
≥77 Ref Ref Ref
61-76 0.87 (0.37-2.01) 0.57 (0.29-1.12) 0.56 (0.28-1.09)
47-60 1.11 (0.62-2.00) 0.69 (0.39-1.21) 0.69 (0.37-1.28)
<47 1.62 (0.90-2.91) 0.76 (0.49-1.19) 0.73 (0.43-1.25)
P trend 0.05 0.57 0.53
eGFR <60 OR (95% CI)
≥75 Ref Ref Ref
50-74 1.02 (0.60-1.75) 0.67 (0.44-1.02) 0.65 (0.40-1.06)
25-49 1.45 (0.87-2.42) 0.73 (0.49-1.07) 0.68 (0.42-1.09)
<25 2.14 (0.80-5.73) 0.73 (0.29-1.80) 0.93 (0.35-2.51)
P trend 0.08 0.33 0.46
* p< 0.05, #p< 0.01, † p< 0.001.
OR - odds ratio, CI – confidence interval.
a unadjusted.
b adjusted for age and gender.
c adjusted for age, gender, diabetes, body mass index, triglycerides,
cardiovascular disease, smoking, season, albuminuria and systolic blood
pressure.lowest quartile (OR 0.73, 95% CI 0.43-1.25, p trend 0.53)
or severe 25(OH)D deficiency (OR 0.93, 95% CI 0.35-
2.51, p trend 0.46) were not significantly associated with
an impaired eGFR. No interactions were found on the
impaired eGFR and vitamin D deficiency relationship by
gender, age or diabetes mellitus (p> 0.10).
Associations between 25(OH)D deficiency and severity
of renal impairment were also examined (Table 3). 25
(OH)D deficiency was significantly associated with an
eGFR <30 in the univariate model (OR 9.31 95% CI
2.11-41.1, p= 0.004), however not upon multivariate ana-
lysis (OR 4.46, 95% CI 0.88-22.7, p= 0.07), when com-
pared to those with an eGFR ≥60.Albuminuria
Albuminuria was present in 6.9% (95% CI 5.7-8.2) of
study participants, with the majority, 85.7% having
microalbuminuria. Participants with 25(OH)D deficiency
were twice as likely to have albuminuria in the un-
adjusted model (OR 2.05, 95% CI 1.58-2.67, p< 0.001)
and the association remained significant when adjusted
for age and gender (OR 1.79, 95% CI 1.40-2.29),
p< 0.001). In the fully adjusted model, subjects with 25
(OH)D deficiency had a 54% increased likelihood of al-
buminuria compared to those without deficiency (OR
1.54, 95% CI 1.14-2.07, p= 0.006).
The effect of vitamin D level was further explored by
dividing the study population into quartiles based on
vitamin D levels (Table 4). Subjects in the quartile with
the lowest 25(OH)D levels had an increased likelihood of
albuminuria compared to those with higher 25(OH)D
levels, in the unadjusted (OR 2.40, 95% CI 1.55-3.73,
p trend <0.001) and fully adjusted (OR 1.48, 95% CI
0.96-2.27, p trend = 0.007) models. When the study
population was divided into population cut-off levels,
25(OH)D levels of <25 nmol/L were significantly asso-
ciated with albuminuria unadjusted OR (2.60, 95% CI,
1.55-3.73, p trend <0.001), but not fully adjusted OR
(1.22, 95% CI 0.42-3.58, p trend 0.13). This may be
explained by the small proportion of participants who
were profoundly vitamin D deficient (n = 310, 2.89%). No
interactions were found on the albuminuria and vitamin
D deficiency relationship by gender, age and diabetes
mellitus (all interaction p> 0.10).
Associations between 25(OH)D deficiency and severity
of albuminuria were also explored (Table 3). Upon multi-
variate analysis, vitamin D deficiency was associated with
an increase in microalbuminuria (OR 1.59, 95% CI, 1.15-
2.21, p= 0.007), but not macroalbuminuria (OR 1.22,
95% CI, 0.76-1.98, p= 0.39), when compared to those
with no albuminuria. This may be explained by the
small proportion of participants (n = 112, 0.9%) with
macroalbuminuria.
Table 3 Associations of 25(OH)D levels and severity of albuminuria and Impaired eGFR
25(OH)D< 50 nmol/L, OR (95% CI)
Model 1a p Model 2b p Model 3c p
No Albuminuria Ref Ref Ref
Micro-albuminuria 2.06 (1.51-2.82) <0.001 1.80 (1.35-2.41) <0.001 1.59 (1.15-2.21) 0.007
Macro-albuminuria 1.99 (0.95-4.17) 0.07 1.70 (0.92-3.13) 0.09 1.22 (0.76-1.98) 0.39
25(OH)D< 50 nmol/L, OR (95% CI)
Model 1a Model 2b Model 3d
eGFR ≥60 Ref Ref Ref
eGFR 30-59 1.25 (0.78-2.02) 0.34 0.79 (0.53-1.16) 0.22 0.84 (0.56-1.26) 0.39
eGFR <30 9.31 (2.11-41.1) 0.004 5.93 (1.20-29.2) 0.03 4.46 (0.88-22.7) 0.07
CI – confidence interval, OR – odds ratio.
a unadjusted.
b adjusted for age and gender.
c adjusted for age, gender, diabetes, body mass index, triglycerides, cardiovascular disease, smoking, season, glomerular filtration rate and systolic blood pressure.
d adjusted for age, gender, diabetes, cholesterol, triglycerides, body mass index, smoking, ethnicity, cardiovascular disease, albuminuria and systolic blood pressure.
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In a large, general-population cohort, 25(OH)D deficiency
was common and independently associated with prevalent
albuminuria. The association between serum 25(OH)D
and albuminuria was most pronounced in those with a 25
(OH)D level in the lowest quartile (<47 nmol/L) and
remained significant in the multivariate model. Our study
did not demonstrate a significant association between 25
(OH)D deficiency and an impaired eGFR.
The association between 25(OH)D deficiency and albu-
minuria was also described in the NHANES III cohort
[16]. Both this study and ours are similar in that they are
general population based surveys with a low prevalenceTable 4 albuminuria regression models - vitamin D
quartiles study population & population cut-off points
Albuminuria OR (95% CI)
25(OH)D level nmol/L Model 1a Model 2b Model 3c
≥77 Ref Ref Ref
61-76 1.00 (0.66-1.53) 0.82 (0.55-1.22) 0.73 (0.48-1.11)
47-60 1.40 (0.93-2.10) 1.14 (0.80-1.62) 1.02 (0.72-1.44)
<47 2.40 (1.55-3.73)† 1.87 (1.26-2.76)# 1.48 (0.96-2.27)
P trend <0.001 <0.001 0.007
Albuminuria OR (95% CI)
≥75 Ref Ref Ref
50-74 1.15 (0.81-1.67) 0.96 (0.70-1.34) 0.86 (0.62-1.19)
25-49 2.20 (1.42-3.40)# 1.74 (1.18-2.56)# 1.42 (0.93-2.16)
<25 2.60 (1.02-6.64)* 1.84 (0.42-56.5) 1.22 (0.42-3.58)
P trend <0.001 0.005 0.13
*p< 0.05, #p< 0.01, †p< 0.001.
OR - odds ratio, CI – confidence interval.
a unadjusted.
b adjusted for age and gender.
c adjusted for age, gender, diabetes, body mass index, triglycerides,
cardiovascular disease, smoking, season, glomerular filtration rate and systolic
blood pressure.of advanced CKD. Nevertheless the NHANES III cohort
differs to our study population, with a lower prevalence
of 25(OH)D deficiency (22.2% versus 30.7), a higher
prevalence of albuminuria (11.6% versus 6.9%), and
hypertension (30.9% versus 22.5%), and greater ethnic
diversity (non-Caucasians, 54.1% versus 87.3), The
consistency of this finding in two, large cohorts high-
lights the robust nature of this association. This associ-
ation was also demonstrated in a CKD cohort from the
SEEK (Study of Early Evaluation of Chronic Kidney
Disease) study [19], where 25(OH)D deficiency was inde-
pendently associated with prevalent albuminuria.
Plausible mechanistic links exist between serum
25(OH)D deficiency and albuminuria. Activation of the
Wnt/β-catenin signaling pathway induces podocyte in-
jury in animal models [32], and this pathway can be
blocked by paricalcitol administration [33]. A number of
experimental studies demonstrate the reno-protective
effects of vitamin D, likely mediated through the RAS
and NF-κB [34]. Mice lacking the vitamin D receptor or
α-hydroxylase (required for vitamin D activation), consti-
tutively over-express renin and develop hypertension
[35]. In animal models of renal injury, vitamin D analo-
gues have been shown to attenuate interstitial fibrosis
[36], glomerulosclerosis [37] and CKD progression [38].
Vitamin D is known to decrease renin gene transcription
[9], and administration of vitamin D analogues resulted
in decreased renin expression and consequently reduced
Angiotensin II expression [39]. As Angiotensin II is a key
mediator of proteinuria and kidney damage through
haemodynamic (vasoconstriction) and non-haemodynamic
(cell proliferation, fibrosis, oxidative stress) means [40],
this is one likely mechanism of the protection afforded by
vitamin D.
NF-κB is involved in the regulation of inflammatory
cytokines and may promote inflammation and fibrogenesis
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blasts derived from mice lacking the vitamin D receptor
have intrinsic activation of NF-κB [10]. This appears rele-
vant to kidney disease as administration of paricalcitol to
mice with experimental obstructive nephropathy was
found to block NF-κB and attenuate tubule-interstitial in-
flammation [36]. Inflammatory cytokines such as trans-
forming growth factor-β and monocyte chemo-attractant
protein-1 have been implicated in the pathogenesis of
nephropathy [42,43]. In a study of CKD patients, low levels
of vitamin D metabolites were associated with increased
inflammatory parameters [44].
Clinical studies have examined the effects of vitamin D
on proteinuria in CKD. Calcitriol and paricalcitol admin-
istration reduced proteinuria in patients with IgA [45]
and diabetic nephropathy [46], already on RAS blockade.
In a recent study high dose cholecalciferol, showed a re-
duction in proteinuria in patients with diabetic nephro-
pathy on RAS blockade [42]. The significant increase in
serum calcitriol level observed also highlight the import-
ant role of paracrine calcitriol synthesis in mediating the
“non-classical” effects of vitamin D. Interestingly pro-
teinuria can also contribute to 25(OH)D deficiency
through a decrease in the megalin-mediated reuptake of
25(OH)D in the proximal tubule [47], however this is
only likely to be of clinical significance in cases of heavy
proteinuria.
In our study cohort with a low prevalence of severe
renal impairment, we did not demonstrate a significant
relationship between serum 25(OH)D levels and
impaired eGFR in the multivariate models, which is con-
sistent with the NHANES III data [48]. Our study did
show an association between 25(OH)D deficiency and an
eGFR <30, however this was lost upon multivariate ad-
justment. Longitudinal studies demonstrate an associ-
ation between 25(OH)D deficiency and progression to
ESKD. In 13,328 participants from NHANES III, 25(OH)
D levels <15 ng/ml (<38 nmol/L) were significantly
more likely to progress to ESKD over a median follow-
up of 9.1 years [17]. In 1705 participants aged 65 years
and older, 25(OH)D <15 ng/ml were associated with
more rapid GFR loss [18]. In a smaller study of mild-
moderate CKD, low 25(OH)D levels were associated with
increased likelihood of CKD progression [20].
The association between low serum 25(OH)D levels
and CKD progression, but not prevalence of low eGFR
may be important. It is clear that many among the gen-
eral community with stage 3 CKD do not progress [49].
As low serum 25(OH)D is associated with albuminuria
and renal inflammation – two key predictors of CKD
progression, it may well be that low serum 25(OH)D
may be a useful marker of risk progression amongst
those with a lower eGFR. It is possible that GFR derived
with new equations that use cystatin C alone, or incombination with creatinine, may allow for better strati-
fication of patients [50], and help to delineate any poten-
tial associations. Given the generally slow rate of CKD
progression, it is possible that longitudinal analysis may
differentiate between stable and progressive CKD and
better delineate this association.
The strengths of this study include the recruitment of
a large, national, population-based cohort, a standar-
dized interview and examination process, and all bio-
chemical measurements being performed in a central
laboratory. In contrast to previous population-based
studies, the prevalence of impaired renal function is
more likely to reflect clinically significant renal impair-
ment given the use of the CKD-EPI equation and cali-
brated enzymatic serum creatinine. However, there are
also several limitations. The cross-sectional design does
not infer causality and the associations described may be
confounded by unknown and unmeasured factors. The
baseline 25(OH)D levels may not be an accurate reflec-
tion of lifetime 25(OH)D levels, however one recent
study suggests that vitamin D status tends to remain
stable over time [51]. Calcitriol levels and additional
markers of mineral metabolism (phosphate, parathyroid
hormone and fibroblast growth factor-23) were not
measured and these may confound the relationship be-
tween 25(OH)D levels and CKD progression. Similarly
biochemical markers of the RAS, such as plasma renin
levels were also not recorded. Serum creatinine and al-
buminuria were recorded with a single measurement,
introducing the potential for misclassification bias. Cal-
citriol use and vitamin D supplementation were not
recorded. It is likely that calcitriol use would be negli-
gible given the low prevalence of CKD and local pre-
scribing guidelines. Similarly any prolonged use of
vitamin D or multi-vitamin supplements should be
reflected in the serum 25(OH)D levels. Medications
known to affect CKD progression, in particular ACE-
inhibitors and angiotensin receptor blockers were also
not recorded. These medications are likely to confer a
protective benefit over and above that of blood pressure
control, and their use may therefore decrease any posi-
tive effect of vitamin D observed.
Conclusions
Many questions regarding the role of vitamin D in CKD
remain unanswered. The optimal 25(OH)D levels are not
well established and may vary depending on the under-
lying disease state and population studied. It is also not
clear how accurately serum 25(OH)D levels reflect local
tissue concentrations, which is paramount given the im-
portance of autocrine vitamin D synthesis in mediating
its extra-renal effects and proposed benefits. Finally, the
ideal way to replace vitamin D is still not clear, and this
may also depend on the clinical situation. The exact role
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evaluation given the traditional propensity of nephrolo-
gists to prescribe “active” vitamin D compounds.
In summary, our study demonstrates a strong associ-
ation between 25(OH)D deficiency and albuminuria but
not impaired eGFR. Given the associations described,
taken together with the limited clinical data and more
compelling experimental data demonstrating kidney pro-
tective effects of vitamin D, it is tempting to speculate
that the correction of vitamin D deficiency may present
a novel, strategy to delay CKD progression. These results
need prospective evaluation and validation in adequately
powered, interventional trials examining the effect of
vitamin D on the reduction of proteinuria. More import-
antly, these studies will need to demonstrate a reduction
in meaningful clinical end-points such as a decrease in
ESKD and mortality.
Abbreviations
25(OH)D: 25-hydroxyvitamin D; GFR: Glomerular filtration rate; CKD: Chronic
kidney disease; CKD-EPI: Chronic kidney disease epidemiology collaboration;
eGFR: Estimated glomerular filtration rate; ACR: Albumin to creatinine ratio;
OR: Odds ratio; CI: Confidence interval; RAS: Renin angiotensin system;
NHANES: National health and nutrition examination survey; ESKD: End-stage
kidney disease; CLIA: Chemiluminescent immunoassay.
Competing interests
The authors’ have no competing interests to declare.
Authors’ contributions
MJD; main statistical analysis and manuscript preparation, contribution to
study design, interpretation of data. DJM; manuscript preparation and
contribution to study design, interpretation of data. RMD; manuscript
preparation and contribution to study design, interpretation of data. CG;
manuscript preparation and contribution to study design, interpretation of
data. ZXL; manuscript preparation and contribution to study design,
biochemical analysis of vitamin D and serum Cr, interpretation of data. PRE;
manuscript preparation and contribution to study design, interpretation of
data. SJC; manuscript preparation and contribution to study design,
interpretation of data. RCA; manuscript preparation and contribution to study
design, interpretation of data. PGK; manuscript preparation and contribution
to study design, interpretation of data. JES; manuscript preparation and
contribution to study design, interpretation of data. KRP: statistical analysis
and manuscript preparation, contribution to study design, interpretation of
data. All authors read and approved the final manuscript.
Acknowledgements
The AusDiab study co-ordinated by the Baker IDI Heart and Diabetes
Institute, gratefully acknowledges the generous support given by: National
Health and Medical Research Council (NHMRC grant 233200), Australian
Government Department of Health and Ageing. Abbott Australasia Pty Ltd,
Alphapharm Pty Ltd, Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City
Health Centre-Diabetes Service-Canberra, Department of Health and
Community Services – Northern Territory, Department of Health and Human
Services – Tasmania, Department of Health –New South Wales, Department
of Health – Western Australia, Department of Health – South Australia,
Department of Human Services – Victoria, Diabetes Australia, Diabetes
Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward
Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney
Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck
Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals,
Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics
Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, Sanofi
Synthelabo.
M.D is supported by the National Health and Medical Research Council of
Australia Scholarship 1017452 and the Royal Australasian College ofPhysicians - Jacquot Foundation. R.M.D is supported by a National Health
and Medical Research Council (NHMRC) Career Development Award (ID
425849). C.G. is supported by a research salary from Laval University.
The authors would like to thank DiaSorin for subsidising the Liaison 25OH
vitamin D reagents and Melbourne Pathology for providing the technical
support for the analysis of 25(OH)D levels in the AusDiab cohort. We are also
enormously grateful to all the AusDiab participants and staff.
Author details
1Department of Nephrology, Monash Medical Centre, 246 Clayton Road,
Clayton 3168, Victoria, Australia. 2Monash University, Wellington Rd, Clayton
3168, Victoria, Australia. 3Baker IDI Heart and Diabetes Institute, 75
Commerical Rd, Melbourne 3004, Victoria, Australia. 4School of Exercise and
Nutrition Sciences, Deakin University, Burwood Hwy, Burwood 3125, Victoria,
Australia. 5Centre de recherche du CHUQ, 2325, rue de l'Université, Québec
(Québec), Quebec G1V 0A6, Canada. 6Melbourne Pathology, 103 Victoria
Parade, Collingwood 3066, Victoria Australia. 7NorthWest Academic Centre,
University of Melbourne, Western Health, 176 Furlong Road, St Albans 3021,
Victoria, Australia. 8Department of Nephrology and Transplantation, Royal
Prince Alfred Hospital, Missenden Road, Camperdown 2005 NSW, Australia.
9Sydney Medical School, University of Sydney, Sydney 2006 NSW, Australia.
Received: 2 May 2012 Accepted: 21 June 2012
Published: 3 July 2012References
1. Adams JS, Hewison M: Update in vitamin D. J Clin Endocrinol Metab 2010,
95(2):471–478.
2. Holick MF: Vitamin D deficiency. N Engl J Med 2007, 357(3):266–281.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F,
Levey AS: Prevalence of chronic kidney disease in the United States.
JAMA 2007, 298(17):2038–2047.
4. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of
oral calcitriol with improved survival in nondialyzed CKD. J Am Soc
Nephrol 2008, 19(8):1613–1619.
5. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli
C, Rodriguez-Puyol D, Cannata-Andia JB: Oral active vitamin D is
associated with improved survival in hemodialysis patients. Kidney Int
2008, 74(8):1070–1078.
6. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr,
Thadhani R: Activated injectable vitamin D and hemodialysis survival: a
historical cohort study. J Am Soc Nephrol 2005, 16(4):1115–1125.
7. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang
Y, Camargo CA Jr, Tonelli M, et al: Vitamin D levels and early mortality
among incident hemodialysis patients. Kidney Int 2007, 72(8):1004–1013.
8. Cunningham J, Zehnder D: New vitamin D analogs and changing
therapeutic paradigms. Kidney Int 2011, 79(7):702–707.
9. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J: Vitamin D: a
negative endocrine regulator of the renin-angiotensin system and blood
pressure. J Steroid Biochem Mol Biol 2004, 89–90(1–5):387–392.
10. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC: Increased NF-
kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol
Endocrinol Metab 2006, 291(2):E315–E322.
11. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, Marz W:
Independent association between 1,25-dihydroxyvitamin D, 25-
hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen
Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 2010, 411
(17–18):1354–1360.
12. Li YC: Renoprotective effects of vitamin D analogs. Kidney Int 2010, 78
(2):134–139.
13. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G: Urinary protein
excretion rate is the best independent predictor of ESRF in non-diabetic
proteinuric chronic nephropathies. "Gruppo Italiano di Studi
Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998, 53(5):1209–1216.
14. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP,
Young J, Rashkow A, Joyce C, et al: Albuminuria and risk of cardiovascular
events, death, and heart failure in diabetic and nondiabetic individuals.
JAMA 2001, 286(4):421–426.
15. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL,
Teschan PE: Predictors of the progression of renal disease in the
Modification of Diet in Renal Disease Study. Kidney Int 1997, 51(6):1908–1919.
Damasiewicz et al. BMC Nephrology 2012, 13:55 Page 8 of 8
http://www.biomedcentral.com/1471-2369/13/5516. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25-
Hydroxyvitamin D levels and albuminuria in the Third National Health and
Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007, 50(1):69–77.
17. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P:
25-hydroxyvitamin D levels, race, and the progression of kidney disease.
J Am Soc Nephrol 2009, 20(12):2631–2639.
18. de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, Siscovick DS,
Kestenbaum B: Serum 25-hydroxyvitamin D and change in estimated
glomerular filtration rate. Clin J Am Soc Nephrol 2011, 6(9):2141–2149.
19. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A: Vitamin D
deficiency, inflammation, and albuminuria in chronic kidney disease:
complex interactions. J Ren Nutr 2011, 21(4):295–302.
20. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F,
Zoccali C: Vitamin D levels and patient outcome in chronic kidney
disease. Kidney Int 2009, 75(1):88–95.
21. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins
D, Adler SG, Norris KC: Chronic kidney disease, hypovitaminosis D, and
mortality in the United States. Kidney Int 2009, 76(9):977–983.
22. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S: Vitamin D status and
mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney
Dis 2011, 58(3):374–382.
23. Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M,
Jolley D, McCarty DJ: The Australian Diabetes, Obesity and Lifestyle Study
(AusDiab)–methods and response rates. Diabetes Res Clin Pract 2002, 57
(2):119–129.
24. Polkinghorne KR, Su Q, Chadban SJ, Shaw JE, Zimmet PZ, Atkins RC: Population
prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle
(AusDiab) study: immunonephelometry compared with high-performance
liquid chromatography. Am J Kidney Dis 2006, 47(4):604–613.
25. Magliano DJ, Barr EL, Zimmet PZ, Cameron AJ, Dunstan DW, Colagiuri S,
Jolley D, Owen N, Phillips P, Tapp RJ, et al: Glucose indices, health
behaviors, and incidence of diabetes in Australia: the Australian
Diabetes, Obesity and Lifestyle Study. Diabetes Care 2008, 31(2):267–272.
26. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K,
Grantham N, Ebeling PR, Daly RM: Serum 25-hydroxyvitamin D, calcium
intake, and risk of type 2 diabetes after 5 years: results from a national,
population-based prospective study (the Australian Diabetes, Obesity
and Lifestyle study). Diabetes Care 2011, 34(5):1133–1138.
27. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney
RP, Murad MH, Weaver CM: Evaluation, treatment, and prevention of
vitamin D deficiency: an Endocrine Society clinical practice guideline.
J Clin Endocrinol Metab 2011, 96(7):1911–1930.
28. Vitamin D and adult bone health in Australia and New Zealand: a
position statement. Med J Aust 2005, 182(6):281–285.
29. KDOQI Clinical Practice Guidelines and Clinical Practice
Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney
Dis 2007, 49(2 Suppl 2):S12–S154.
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI,
Kusek JW, Eggers P, Van Lente F, Greene T, et al: A new equation to
estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604–612.
31. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1–S266.
32. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y: Wnt/beta-catenin
signaling promotes podocyte dysfunction and albuminuria. J Am Soc
Nephrol 2009, 20(9):1997–2008.
33. He W, Kang YS, Dai C, Liu Y: Blockade of Wnt/beta-catenin signaling by
paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol
2011, 22(1):90–103.
34. Li YC: Vitamin D: roles in renal and cardiovascular protection. Curr Opin
Nephrol Hypertens 2012, 21(1):72–79.
35. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3)
is a negative endocrine regulator of the renin-angiotensin system. J Clin
Invest 2002, 110(2):229–238.
36. Tan X, Li Y, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in
obstructive nephropathy. J Am Soc Nephrol 2006, 17(12):3382–3393.
37. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S,
Abe H, Kuze K, Fukatsu A, Kita T, et al: A vitamin D analog ameliorates
glomerular injury on rat glomerulonephritis. Am J Pathol 2001, 158
(5):1733–1741.
38. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T,
Slatopolsky E: Combination therapy with an angiotensin-convertingenzyme inhibitor and a vitamin D analog suppresses the progression of
renal insufficiency in uremic rats. J Am Soc Nephrol 2007, 18(6):1796–1806.
39. Qiao G, Kong J, Uskokovic M, Li YC: Analogs of 1alpha,25-dihydroxyvitamin
D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol
2005, 96(1):59–66.
40. Ruster C, Wolf G: Renin-angiotensin-aldosterone system and progression
of renal disease. J Am Soc Nephrol 2006, 17(11):2985–2991.
41. Guijarro C, Egido J: Transcription factor-kappa B (NF-kappa B) and renal
disease. Kidney Int 2001, 59(2):415–424.
42. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, Mayr M, Tam
FW: Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in
patients with type 2 diabetic nephropathy on established renin-
angiotensin-aldosterone system inhibition. Kidney Int 2011, 80(8):851–860.
43. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH:
Monocyte chemoattractant protein-1-induced tissue inflammation is
critical for the development of renal injury but not type 2 diabetes in
obese db/db mice. Diabetologia 2007, 50(2):471–480.
44. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV,
Raymond NT, Howie AJ, Cockwell P, Stewart PM, et al: Reduction of the
vitamin D hormonal system in kidney disease is associated with
increased renal inflammation. Kidney Int 2008, 74(10):1343–1353.
45. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK: Oral calcitriol for
the treatment of persistent proteinuria in immunoglobulin A
nephropathy: an uncontrolled trial. Am J Kidney Dis 2008, 51(5):724–731.
46. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving
HH, Pritchett Y, Remuzzi G, Ritz E, et al: Selective vitamin D receptor
activation with paricalcitol for reduction of albuminuria in patients with
type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010,
376(9752):1543–1551.
47. Dusso AS, Tokumoto M: Defective renal maintenance of the vitamin D
endocrine system impairs vitamin D renoprotection: a downward spiral
in kidney disease. Kidney Int 2011, 79(7):715–729.
48. Chonchol M, Scragg R: 25-Hydroxyvitamin D, insulin resistance, and
kidney function in the Third National Health and Nutrition Examination
Survey. Kidney Int 2007, 71(2):134–139.
49. White SL, Polkinghorne KR, Atkins RC, Chadban SJ: Comparison of the
prevalence and mortality risk of CKD in Australia using the CKD
Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal
Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian
Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010, 55(4):660–670.
50. Eriksen BO, Mathisen UD, Melsom T, Ingebretsen OC, Jenssen TG, Njolstad I,
Solbu MD, Toft I: The role of cystatin C in improving GFR estimation in
the general population. Am J Kidney Dis 2012, 59(1):32–40.
51. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G:
Tracking of serum 25-hydroxyvitamin D levels during 14 years in a
population-based study and during 12 months in an intervention study.
Am J Epidemiol 2010, 171(8):903–908.
doi:10.1186/1471-2369-13-55
Cite this article as: Damasiewicz et al.: 25-hydroxyvitamin D Levels and
chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and
Lifestyle) study. BMC Nephrology 2012 13:55.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
